{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:04Z","timestamp":1794023284723,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01320-x","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:35:36Z","timestamp":1751265336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1320_CR1","unstructured":"Somay K, Azakli H, Chahine JJ, Loughney TM, Ozdemirli M. Is immune effector cell-associated enterocolitis a CAR T- cell lymphoproliferative disorder? Blood Cancer J. 2025."},{"key":"1320_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Moran-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:180.","journal-title":"Blood Cancer J"},{"key":"1320_CR3","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S2152-2650(24)01911-6","volume":"24","author":"N Bar","year":"2024","unstructured":"Bar N, Yee A, Dhakal B, Frigault M, Richard S, Cohen AD, et al. P-008 a rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; insights from a multicenter case series. Clin Lymphoma Myeloma Leuk. 2024;24:S44\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1320_CR4","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1182\/blood-2024-207885","volume":"144","author":"H Hosoya","year":"2024","unstructured":"Hosoya H, Fernandez-Pol S, Gubatan J, Ehlinger Z, Lohman C, Bastidas Torres AN, et al. Indolent CD8+ CAR T-Cell lymphoma of the gastrointestinal tract after ciltacabtagene autoleucel therapy for relapsed\/refractory multiple myeloma. Blood. 2024;144:4846.","journal-title":"Blood"},{"key":"1320_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4+ T-Cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl J Med. 2025;392:577\u201383.","journal-title":"N. Engl J Med"},{"key":"1320_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11:219.","journal-title":"Nat Commun"},{"key":"1320_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/1097-0142(19930401)71:7<2335::AID-CNCR2820710727>3.0.CO;2-D","volume":"71","author":"DL Cooper","year":"1993","unstructured":"Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Saidman BH, Davis CA, et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993;71:2335\u201341.","journal-title":"Cancer"},{"key":"1320_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","volume":"122","author":"AM Perry","year":"2013","unstructured":"Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122:3599\u2013606.","journal-title":"Blood"},{"key":"1320_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood. 2023;142:1248\u201352.","journal-title":"Blood"},{"key":"1320_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3:711\u20137.","journal-title":"Blood Adv"},{"key":"1320_CR11","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther. 2023;29:438.e1\u2013438.e16.","journal-title":"Transpl Cell Ther"},{"key":"1320_CR12","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435.","journal-title":"J Immunother Cancer"},{"key":"1320_CR13","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.14309\/crj.2018.17","volume":"5","author":"P Diana","year":"2018","unstructured":"Diana P, Mankongpaisarnrung C, Atkins MB, Zeck JC, Charabaty A. Emerging role of vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis. ACG Case Rep J. 2018;5:e17.","journal-title":"ACG Case Rep J"},{"key":"1320_CR14","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.2024.42.16_suppl.2661","volume":"42","author":"Y Wang","year":"2024","unstructured":"Wang Y, Varatharajalu K, Shatila M, Junek K, Ninoska NN, Msaouel P, et al. Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis. J Clin Oncol. 2024;42:2661.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01320-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01320-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01320-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:35:37Z","timestamp":1751265337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01320-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01320-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB reports consulting: Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Gilead\/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Poseida Therapeutics, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. LM reports consulting or advisory role for Legend Biotech and BioLineRx. DKH reports consulting: BMS, Janssen, Legend Biotech, Pfizer, Karyopharm, Kite Pharma, AstraZeneca; Research: BMS, Janssen, Kite Pharma, Karyopharm, Adaptive Biotechnologies, and Pentecost Myeloma Research Center. JLW reports consulting: Adaptive. YL reports consulting: Janssen, Legend, Celgene, Sanofi, BMS, Pfizer, Regeneron, Genentech, NexImmune, Caribou; research funding: Janssen, Celgene, BMS. The remaining authors have no conflicts to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}